Adaptive Biotechnologies Corp revenue
Adaptive Biotechnologies Corp's revenue was $277m in fiscal 2025, up 54.8% on the year before. Since fiscal 2017 ($38.4m) it has grown at a compound 28.0% a year. Over the last twelve months it was $308m.
Revenue history
| Fiscal year | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38 | 56 | 85 | 98 | 154 | 185 | 170 | 179 | 277 | 308 |
| Growth on the year before | — | +44.8% | +52.8% | +15.6% | +56.9% | +20.1% | −8.1% | +5.1% | +54.8% | — |
| Gross profit | 23 | 36 | 63 | 76 | 105 | 127 | 95 | 107 | 206 | 233 |
| Gross margin | 59.2% | 64.7% | 73.8% | 77.1% | 68.1% | 68.7% | 55.6% | 59.7% | 74.2% | 75.6% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Mrd Business | $212M | 76.7% | ▲ 45.9% |
| Immune Medicine Business | $64.6M | 23.3% | ▲ 93.4% |
From Adaptive Biotechnologies Corp's 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Adaptive Biotechnologies Corp | $308m | 50.1% | 17.6% |
| Vericel Corp | $306m | 23.0% | 19.8% |
| Vir Biotechnology, Inc. | $303m | 1495.9% | -14.8% |
| Arvinas, Inc. | $317m | -15.0% | 26.1% |
| Iovance Biotherapeutics, Inc. | $325m | 34.5% | — |
| Syndax Pharmaceuticals Inc | $290m | 159.7% | 177.8% |
Compare with peers
- Vericel Corp revenue
- Vir Biotechnology, Inc. revenue
- Arvinas, Inc. revenue
- Iovance Biotherapeutics, Inc. revenue
- Syndax Pharmaceuticals Inc revenue
Head to head: ADPT vs VCELADPT vs VIRADPT vs ARVNADPT vs IOVA
More: Biotechnology stocks compared, Health Care sector, rankings of US companies